‘The right big idea at the right time’

On a Sunday evening drive back to Brooklyn, Whit Bernard ’13 MBA pulled to the side of the road, took out his iPhone and dotted the final “i” on an acquisition deal worth billions.

Or so he thought.

That late summer 2025 weekend was filled with continuous calls between Bernard and counterparts at Pfizer, bankers, board members, and mergers and acquisitions attorneys. The agreement would have seen Metsera — a company developing obesity and diabetes treatments cofounded by Bernard — acquired by one of America’s largest biomedical corporations. 

Enter Novo Nordisk. An unsolicited proposal from the company prompted a two-week bidding war, in which Pfizer and Novo increased their offers numerous times.

“On a Friday evening in early November we finally reached a point as a board when it became clear that the back-and-forth was over, and we declared Pfizer’s most recent proposal superior,” says Bernard, chief executive officer at Metsera and a managing partner at Population Health Partners (PHP). 

For Bernard, it was part of a journey that started 12 years earlier when he enrolled in the Two-Year MBA Program.

“At that time, I was a ‘recovering musician’ looking to pivot my career,” he recalls. “Kellogg helped build a foundation that has been instrumental in my success.”

From MBA to McKinsey to Metsera

After finishing his MBA at Kellogg, Bernard was recruited to McKinsey & Company, which is where he says he learned a lot about healthcare and biopharma. Following four years of advising large pharma companies, Bernard transitioned to focusing more on biotech and mid-cap pharma. One of his clients was Clive Meanwell, CEO of The Medicines Company. 

“I somehow talked Clive into hiring me to lead commercial strategy and business development at The Medicines Company and wound up leading the process of selling it to Novartis about 18 months later,” says Bernard. “It was an incredible learning experience, and I've been working with Clive ever since.”

Following that initial $9.7 billion acquisition, Bernard and Meanwell teamed with several former colleagues to found Population Health Partners in early 2020. Inspired by an observation that biopharma had shifted its business model dramatically away from primary care and consumer health to high-end specialty diseases, PHP saw therapeutics targeting prevalent diseases as undervalued.

“At PHP, we sought to build important, impactful companies at scale,” Bernard says. “We were fortunate enough to align with big sources of strategic capital, including Bain (Areteia) and ARCH (Metsera) which made this possible, and we brough a network of excellent operators from The Medicines Company and elsewhere to accelerate our efforts. It turned out to be the right big idea at the right time.”

The forefront of healthcare

Some of the biggest-selling drugs in 2025 were GLP-1/GIP medications Zepbound, Mounjaro and Ozempic. “Not a bad time to be two years into the standup of an obesity biotech,” says Bernard.

“By the time we founded Metsera I had close to a decade working in and around biopharma, which stacked on top of my Kellogg training,” he says, recalling that he suddenly found himself working in a consumer-dominated world. “Out of nowhere, I found myself digging up notes from classes with Professors Tim Calkins and Julie Hennessy. My Kellogg education helped me think through how to align our portfolio strategy and development plans to consumer needs and preferences and how to rally a leadership team with a strong medical bias towards a consumer products mindset.” 

As a managing partner at PHP, Bernard works alongside a team of innovators, strategists and veteran drug developers to build new companies and advance new technologies with the potential for transformative impact on highly prevalent diseases.

That battle for Metsera, and $10 billion acquisition by Pfizer, positions PHP to explore new projects in fields ranging from cardiovascular prevention to allergy and sleep to menopause. “We’re doubling down on our focus to build leading companies that enhance the treatment of prevalent diseases, with a renewed focus on the concept of ‘healthspan,’ which we think will play a pivotal role in healthcare innovation over the next two decades,” says Bernard. “What’s exciting about healthspan as a metric is that it brings together what major economies and health systems need: increased productivity later in life and reduced spend on preventable morbidity; with what consumers want: a fuller, healthier and longer life.” 

Over the years, Bernard has stayed connected with the school, taking part in a fireside chat with Craig Garthwaite, faculty director of Healthcare at Kellogg, at an alumni event in New York City in December. He is also taking part in the Healthcare Entrepreneurship Forum on April 17, 2026, at the Global Hub in Evanston.  

As he begins this latest chapter, Bernard credits Kellogg with providing the marketing acumen, leadership skills and rigorous mindset to succeed. 

“Kellogg was a complete professional reset for me — establishing foundational skills ranging from strategy to marketing to organizational change to analytics,” he says. “Mine is not a linear story, and so I encourage students from non-traditional backgrounds to never doubt what's possible.”

Read Next: No one goes it alone: How Healthcare at Kellogg’s community fuels growth in the industry